Atopic Dermatitis Clinical Trials in Birmingham, Alabama

8 studies are recruiting for atopic dermatitis in Birmingham, Alabama right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

   This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrociti…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Cahaba Dermatology & Skin Health Center, Birmingham, Alabama

   Locations

   41 in total

   Run by

   Pfizer

   See if you can join NCT06807281 on ClinicalTrials.gov

2. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   AllerVie Clinical Research, Birmingham, Alabama

   Locations

   85 in total

   Run by

   Apollo Therapeutics Ltd

   See if you can join NCT07599813 on ClinicalTrials.gov

3. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

   This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Novartis Investigative Site, Birmingham, Alabama

   Locations

   105 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06947993 on ClinicalTrials.gov

4. This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

   The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. …

   Stage

   Not phased

   Ages

   12 and older

   Site

   Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham, Alabama

   Locations

   79 in total

   Run by

   Sanofi

   See if you can join NCT07290803 on ClinicalTrials.gov

5. A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

   The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of …

   Stage

   Phase 3

   Ages

   0 to 11

   Site

   Leo Pharma Investigational site, Birmingham, Alabama

   Locations

   72 in total

   Run by

   LEO Pharma

   See if you can join NCT06311682 on ClinicalTrials.gov

6. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham, Alabama

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov

7. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

   The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Allervie Clinical Research, Birmingham, Alabama

   Locations

   98 in total

   Run by

   Pfizer

   See if you can join NCT05995964 on ClinicalTrials.gov

8. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

   The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

   Stage

   Not phased

   Ages

   12 and older

   Site

   Galderma Investigational Site - 8893, Birmingham, Alabama

   Locations

   108 in total

   Run by

   Galderma R&D

   See if you can join NCT06988605 on ClinicalTrials.gov